Optometrists recognize the vital role of clinical trials in advancing eye care. A significant challenge, however, is meeting enrollment targets within set timelines. At the 2024 American Academy of Optometry meeting in Indianapolis, Andrew Pucker from Lexitas Pharma Services presented data on enrollment rates and trends in North America.
Comprehensive Analysis of Ophthalmic Trials
Pucker's team analyzed every clinical trial registered in the United States, categorized by study phase and common ophthalmic indications like glaucoma, dry eye, and macular degeneration. This detailed breakdown offers benchmarks for enrollment, site needs, and study duration. For instance, a typical phase 2 dry eye study needs about 100 subjects and 20 clinical sites, averaging 6 months to complete. This data helps researchers forecast resource needs and improve enrollment success.
Key Industry Players
The analysis also highlighted leading industry sponsors in ophthalmic clinical trials. Alcon and Allergan are prominent, showing their dedication to eye care innovation. This information can help optometrists find collaborators and stay updated on developments.
Practical Implications for Optometrists
Pucker's work bridges the gap between theory and practice in clinical research. Understanding enrollment trends and sponsor activities allows optometrists to better participate in trials, contribute to eye care advancements, and provide patients with access to promising treatments. The full dataset is in the Optometry and Vision Science journal, and Pucker offers his presentation poster to interested individuals. This information is crucial for optimizing enrollment, streamlining study design, and driving innovation in eye care.
